Effects of subcutaneously implanted sustained-release cyclophosphamide capsules on Walker 256 solid rat tumor

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery Systems

Background:

• Solid tumors pose significant treatment challenges.
• Conventional chemotherapy administration can lead to systemic toxicity.
• Novel drug delivery methods are needed to improve localized cancer treatment efficacy.

Purpose of the Study:

• To evaluate the efficacy of a sustained-release cyclophosphamide implant for treating solid tumors.
• To assess the impact of localized cyclophosphamide delivery on tumor regression and surrounding tissue.
• To explore an alternative administration route for cytotoxic chemotherapy.

Main Methods:

• Walker 256 solid rat tumor model was utilized.
• Subcutaneous implantation of a single sustained-release cyclophosphamide capsule adjacent to the tumor.
• Comparison with untreated control animals.

Main Results:

• Complete tumor regression observed in rats treated with sustained-release cyclophosphamide.
• Tumor regression occurred within 28 days post-implantation.
• Regenerated tissues and absence of viable tumor cells noted at the previous tumor site.
• A fibrous sheath formed around the implant over 3 weeks.

Conclusions:

• Sustained-release cyclophosphamide implants can induce complete regression of experimental solid tumors.
• Localized, sustained drug delivery offers a promising alternative to conventional chemotherapy administration.
• This approach warrants further investigation for solid tumor treatment in preclinical models.